A Study to Compare the Relative Bioavailability of Two 200 Mg Tramadol Hydrochloride Tablet Products Under Fasting Conditions

This study has been completed.
Sponsor:
Information provided by:
Labopharm Inc.
ClinicalTrials.gov Identifier:
NCT00834366
First received: January 30, 2009
Last updated: April 25, 2012
Last verified: April 2012
  Purpose

To determine whether the test product, Labopharm Tramadol HCl Once-A-Day (OAD) 200 mg film-coated tablets, and the reference product, Labopharm Tramadol HCl OAD 200 mg uncoated tablets, are bioequivalent.


Condition Intervention Phase
Healthy
Drug: Tramadol HCl
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label

Resource links provided by NLM:


Further study details as provided by Labopharm Inc.:

Primary Outcome Measures:
  • AUC(0-t) [ Time Frame: 48 hours ] [ Designated as safety issue: No ]
    Area under plasma concentration versus time curve to the last measurable concentration. Unit is ng.h/mL. h=hours.

  • AUC(0-Inf) [ Time Frame: 48 hours ] [ Designated as safety issue: No ]
    Area under plasma concentration versus time curve extrapolated to infinity. Unit is ng.h/mL. h=hour.

  • Cmax [ Time Frame: 48 hours ] [ Designated as safety issue: No ]
    Maximum plasma concentration


Secondary Outcome Measures:
  • Tmax [ Time Frame: 48 hours ] [ Designated as safety issue: No ]
    Time to the maximum concentration

  • t1/2 [ Time Frame: 48 hours ] [ Designated as safety issue: No ]
    Apparent terminal elimination half-life


Enrollment: 26
Study Start Date: February 2005
Study Completion Date: March 2005
Primary Completion Date: March 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tramadol HCl 200 mg Film-coated Tablets
Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Film-coated Tablet based on randomization schedule.
Drug: Tramadol HCl
Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Film-coated Tablet or Tramadol HCl 200 mg Uncoated Tablets based on randomization schedule.
Other Name: Tramadol HCl
Experimental: Tramadol HCl 200 mg Uncoated Tablets
Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Uncoated Tablet based on randomization schedule.
Drug: Tramadol HCl
Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Film-coated Tablet or Tramadol HCl 200 mg Uncoated Tablets based on randomization schedule.
Other Name: Tramadol HCl

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male and female subjects 18 to 55 years of age (inclusive).
  • Body mass within 10% of the ideal mass in relation to height and age, according to the Body Mass Index (BMI).
  • Body mass not less than 60 kg.
  • Findings within the range of clinical acceptability in medical history and physical examination, and laboratory results within the "normal ranges" for the relevant laboratory tests (unless the investigator considered the deviation to be irrelevant for the purpose of the study).
  • Normal electrocardiogram (ECG) and vital signs, or abnormalities which the investigator did not consider a disqualification for participation in the study.
  • Willingness to undergo a pre-study physical examination and pre- and post-study laboratory investigations.
  • Ability to comprehend and willingness to sign both statements of informed consent (for screening and phase-related procedures).
  • Non-smoker or past smoker who stopped smoking at least 3 months before entering the study.
  • For females, the following conditions were to be met:

    • had been postmenopausal for at least 2 years, or
    • had been surgically sterilized, or
    • was of childbearing potential, and all of the following conditions were met:

      • had a normal menstrual flow within 1 month before study entry, and
      • had negative serum pregnancy test at screening. If this test was positive, the subject was to have been excluded from the study before receiving study medication. In the rare circumstance that a pregnancy was discovered after the subjects received study drug, then every attempt must be made to follow such subjects to term, and
      • must agree to use an accepted method of contraception (i.e., spermicide and barrier methods or spermicide and Intrauterine Device (IUD)). The subject had to agree to continue with the same method throughout the study. Hormonal contraceptives will not be allowed.

Exclusion Criteria:

  • Evidence of psychiatric disorder, antagonistic personality, poor motivation, emotional or intellectual problems likely to limit the validity of consent to participate in the study or limit the ability to comply with protocol requirements.
  • History of, or current compulsive alcohol abuse (>10 drinks weekly), or regular exposure to other substances of abuse.
  • Use of any medication, prescribed or over-the-counter, within 2 weeks prior to the first administration of study medication except if this would not have affected the outcome of the study in the opinion of the clinical investigator. Use of hormonal contraceptive agents by females were not allowed.
  • Participation in another study with an experimental drug within 8 weeks before the first administration of study medication.
  • Treatment within the previous 3 months with any drug with a well-defined potential for adversely affecting a major organ or system with evidence to this effect.
  • A major illness during the 3 months before commencement of the screening period.
  • History of hypersensitivity to the study drug or any related drugs.
  • History of bronchial asthma.
  • History of epilepsy.
  • Relevant history or laboratory or clinical findings indicative of acute or chronic disease, likely to influence study outcome.
  • Donation or loss of blood equal to or exceeding 500 mL during the 8 weeks before the first administration of study medication.
  • Diagnosis of hypotension made during the screening period.
  • Diagnosis of hypertension made during the screening period or current diagnosis of hypertension.
  • Resting pulse of >100 beats per minute or <45 beats per minute during the screening period, either supine or standing.
  • Positive testing for hepatitis B antigen.
  • Significant liver disease, defined as active hepatitis or elevated liver enzymes (e.g., AST (aspartate aminotransferase), Alanine transaminase (ALT)) >2 times the upper boundary of the normal range.
  • Positive urine screen for drugs of abuse.
  • Positive urine screen for tobacco use (SureStepTM Smoke Check Tests and One-Step Cotinine (COT) Tests).
  • A serum pregnancy test (beta-hCG) either positive or not performed or lactation.
  • History of marijuana, barbiturate, amphetamine or narcotic abuse within 12 months prior to study start.
  • Participation in a tramadol study within the previous 12 months.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Additional Information:
No publications provided

Responsible Party: Sybil Robertson, Vice President, Regulatory Affairs, Labopharm Inc.
ClinicalTrials.gov Identifier: NCT00834366     History of Changes
Other Study ID Numbers: MDT1-013
Study First Received: January 30, 2009
Results First Received: April 6, 2009
Last Updated: April 25, 2012
Health Authority: United States: Food and Drug Administration
South Africa: Medicines Control Council

Keywords provided by Labopharm Inc.:
Healthy volunteers

Additional relevant MeSH terms:
Tramadol
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Therapeutic Uses
Analgesics, Opioid

ClinicalTrials.gov processed this record on July 28, 2014